A Phase I Bridging Study to Evaluate the PK, Safety and Tolerability of SR419 in Healthy Subjects
Latest Information Update: 02 Dec 2024
At a glance
- Drugs SR 419 (Primary)
- Indications Neuropathic pain
- Focus Pharmacokinetics
- Sponsors SIMR Biotech
Most Recent Events
- 28 Feb 2022 Status changed from recruiting to completed.
- 01 Nov 2021 Planned number of patients changed from 32 to 40.
- 01 Nov 2021 Planned End Date changed from 22 Mar 2022 to 31 Dec 2021.